Vaccine Information Statement (VIS) -- Serogroup B Meningococcal Vaccine (MenB): What You Need to Know
This two-page Vaccine Information Statement (VIS) educates people about the serogroup B meningococcal (MenB) vaccines. It explains that meningococcal disease can lead to meningitis and blood infections, and clarifies that though other vaccines are recommended to protect against serogroups A, B, C, W, and Y of the bacteria Neisseria meningitidis, the MenB vaccine can help prevent meningococcal disease caused by serogroup B. It identifies who is at increased risk of getting the disease, and describes transmission and effects. The VIS discusses the two FDA-approved serogroup B meningococcal vaccines, who should receive the vaccine, and when. It identifies who should not get vaccinated, risks and side effects, and what to look for and what to do in the event of a severe allergic reaction, such as reporting the problem to the Vaccine Adverse Event Reporting System (VAERS). Contact information for the National Vaccine Injury Compensation Program (VICP) is provided, along with tips for how people can learn more about the MenB vaccine.
The English-language VIS was created by the Centers for Disease Control and Prevention (CDC) National Center for Immunization and Respiratory Diseases. The translations are provided by the Immunization Action Coalition (IAC) and its partner organizations.
A qualified translation company performed an independent review by a second translator, and a client advocate.